A new alternative therapy in dermatology: tocilizumab.

about

Secukinumab (AIN-457) for the treatment of Psoriasis.Updated treatment strategies for intestinal Behçet's disease.

P2860

Q38662868-F728FFA2-3024-411D-92A4-10665B4FCFF2 Q47327588-7032439C-A507-4DCA-9BE5-226EB9ADFEA8

P2860

A new alternative therapy in dermatology: tocilizumab.

Item

http://www.wikidata.org/entity/Q38507301

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A new alternative therapy in dermatology: tocilizumab.

@en

type

Item

label

A new alternative therapy in dermatology: tocilizumab.

@en

prefLabel

A new alternative therapy in dermatology: tocilizumab.

@en

P1476

A new alternative therapy in dermatology: tocilizumab.

@en

P2093

Göknur Kalkan

http://www.w3.org/2001/XMLSchema#string

Özgül Muştu Koryürek

http://www.w3.org/2001/XMLSchema#string

P2860

Tocilizumab: a review of its use in the management of rheumatoid arthritis

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials.

IL-6 as a druggable target in psoriasis: focus on pustular variants.

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis.

Comparing comparators: a look at control arms in kidney cancer studies over the years.

P304

145-152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/15569527.2015.1049356

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26023856

http://www.w3.org/2001/XMLSchema#string

A new alternative therapy in dermatology: tocilizumab.

about

P2860

P2860

A new alternative therapy in dermatology: tocilizumab.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698